Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE study

Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE study

Background/Purpose: While direct-acting antiviral regimens have been approved for chronic hepatitis C (CHC) patients in Taiwan, reimbursement is limited to certain populations. Thus, pegylated interferon plus ribavirin (PEG-IFN/RBV) remains the standard of care for many patients. The aim of this stu...

Full description

Bibliographic Details
Main Authors: Chen-Hua Liu, Ming-Lung Yu, Cheng-Yuan Peng, Tsai-Yuan Hsieh, Yi-Hsiang Huang, Wei-Wen Su, Pin-Nan Cheng, Chih-Lin Lin, Ching-Chu Lo, Chi-Yi Chen, Jyh-Jou Chen, Qian Ma, Craig Brooks-Rooney, Jia-Horng Kao
Format: Article
Language:English
Published: Elsevier 2019-06-01
Series:Journal of the Formosan Medical Association
Online Access:http://www.sciencedirect.com/science/article/pii/S0929664618302766

Internet

http://www.sciencedirect.com/science/article/pii/S0929664618302766

Similar Items